Associate Professor,Department of Chemistry, Sardar Vallabhabhai Patel Arts and Science College, Ainpur, Dist. Jalgaon, Maharashtra. 425507
The drug discovery process is notoriously time-consuming, costly, and failure-prone. In recent years, artificial intelligence (AI) techniques—including machine learning (ML), deep learning (DL), graph neural networks (GNNs), and generative modelling—have emerged as transformative tools to accelerate and de?risk key stages of discovery and development. Recent studies indicate that AI can reduce drug discovery timelines by up to 30–50% and significantly improve hit identification rates. This review examines the current state of AI applications across the pharmaceutical pipeline: target identification and validation, virtual screening and lead discovery, lead optimisation and de novo design, drug repurposing, ADME/Tox prediction, and clinical trial design. We highlight major challenges and outline future prospects including generative chemistry, multi-modal data integration, federated learning and ethically trustworthy AI. The review concludes that while AI is not a panacea, it is rapidly becoming a critical component of modern drug discovery and offers genuine promise for more efficient, rational therapeutic development..
Developing a novel therapeutic agent remains one of the most challenging endeavours in biomedical science. Traditional drug discovery and development typically spans over a decade, costs on the order of billions of U.S. dollars, and still yields low success rates: only a small percentage of drug candidates that enter clinical trials ever reach the market (1). The complexity arises from multiple bottlenecks: identification of a valid biological target, screening or designing chemical or biologic compounds, optimization of potency, selectivity, pharmacokinetics (PK) and toxicity, preclinical in vivo testing, and clinical trials.
In this context, artificial intelligence (AI) has emerged as a compelling paradigm to help overcome these bottlenecks. AI encompasses a broad set of computational techniques—machine learning (ML), deep learning (DL), natural language processing (NLP), graph?based learning, and generative modelling—that enable pattern recognition, prediction, and generation from large and heterogeneous data. AI has the potential to revolutionize the drug discovery process by enhancing efficiency, accuracy, and speed (2). In recent years, multiple comprehensive review articles have systematically summarized the state of the art in the application of artificial intelligence to drug discovery, highlighting major methodological advances, emerging computational frameworks, and real-world pharmaceutical applications (3-5). ADME/Tox prediction, and clinical trial design. In addition, the manuscript summarizes the major challenges and enabling factors associated with the adoption of AI, as well as future perspectives and emerging trends in this rapidly evolving field. Ultimately, this article aims to build on those contributions by providing a detailed, structured examination of how AI technologies are being applied at each stage of the drug discovery pipeline, highlighting both opportunities and limitations, and suggesting future directions.
2. OVERVIEW OF AI METHODOLOGIES IN DRUG DISCOVERY
AI has become an integral component of modern pharmaceutical and biomedical research, offering powerful computational tools to address the complexity of drug discovery and development. By leveraging machine learning and deep learning algorithms, AI enables efficient analysis of large-scale omics, chemical, and clinical datasets, thereby enhancing target identification, hit discovery, and lead optimization (6). AI-based models also improve the prediction of pharmacokinetic properties, toxicity, and clinical outcomes (7).
2.1 Machine Learning (ML) and Deep Learning (DL)
Machine learning broadly refers to algorithms that ‘learn’ from data to make predictions or decisions without being explicitly programmed for each task. Conventional ML algorithms in drug discovery have included support vector machines (SVMs), random forests (RFs), k?nearest neighbours, logistic regression, gradient boosting, etc. (5). Deep learning represents a subset of ML where artificial neural networks with multiple hidden layers (deep architectures) can automatically learn hierarchical representations of data. DL has proven particularly helpful when handling large, complex datasets such as images, sequences or high-dimensional data.
2.2 Graph Neural Networks (GNNs)
In molecular modeling, molecules are naturally represented as graphs (atoms as nodes, bonds as edges). GNNs have emerged as powerful tools for learning directly from such graph?structured data. Recent reviews (8) emphasize how GNNs are used for molecular property prediction, virtual screening, molecular generation, knowledge?graph construction and synthesis planning. GNNs thus bridge structural chemistry and AI in an elegant way.
2.3 Generative Models and De novo Design
Generative modelling is a class of techniques that learn to generate new data instances similar to the training distribution. In drug discovery, generative approaches (e.g., variational autoencoders, generative adversarial networks (GANs), reinforcement-learning scaffolding, and diffusion models) are used to propose novel chemical structures with desired properties (9). The promise of de novo design is the ability to explore chemical space beyond existing compounds and potentially identify “first?inclass” molecules.
2.4 Knowledge Graphs, Multi-Modal learning and NLP
AI also supports integration of heterogeneous biomedical data: genomics, transcriptomics, proteomics, phenotypic assays, chemical libraries, literature. Knowledge graphs link entities (genes, proteins, compounds, diseases, pathways) and AI can traverse such graphs for hypothesis generation (10-12). NLP and large?language-model (LLM) methods now enable processing of unstructured textual sources (scientific literature, patents) to extract relationships relevant to drug discovery.
2.5 Federated Learning and Data Privacy
Because many drug discovery datasets are proprietary and confidential, federated learning (where models are trained across multiple institutions without sharing raw data) is becoming increasingly important (13). This approach helps preserve data privacy while enabling the use of broader and more diverse training datasets.
2.6 Explainable AI (XAI) and Uncertainty Quantification
As ML/DL models are increasingly used in decision-making, issues of interpretability, transparency, and reliability become paramount. Explainable AI techniques aim to make model predictions more understandable to human scientists (1, 14) Equally, quantifying uncertainty (i.e., confidence in predictions) is critical when deploying AI-driven decisions in high-stakes domains such as drug development.
Collectively, these methodologies form the computational backbone of modern AI-driven drug discovery, enabling data-driven decision-making across the pharmaceutical pipeline. A structured overview of the principal artificial intelligence methodologies employed in drug discovery, including their key characteristics, applications, advantages, and limitations, is presented in Table 1. This overview highlights the diversity of AI approaches used to address complex chemical and biological data, while also emphasizing challenges related to data bias, interpretability, and model generalizability (2, 4, 15).
Table 1: Overview of key AI techniques used in drug discovery
|
AI Method |
Description |
Typical Applications |
Advantages |
Limitations |
|
Machine Learning (ML) |
Algorithms (e.g., SVM, Random Forest) for learning structure–activity relationships |
ADME prediction, toxicity classification, virtual screening. |
Fast training, interpretable (for some methods). |
Limited scalability for high-dimensional data. |
|
Deep Learning (DL) |
Neural networks with multiple layers capable of representation learning. |
Molecular property prediction, image-based phenotypic screening. |
Handles complex data; automates feature generation. |
Requires large labelled datasets, harder to interpret. |
|
Graph Neural Networks (GNNs) |
Models that operate on graph-structured inputs (e.g., molecules). |
Binding prediction, de novo design, molecular optimisation. |
Captures topological molecular features effectively. |
Computationally expensive; still maturing. |
|
Generative Models (VAE, GAN, Diffusion) |
Learn distributions of chemical space to generate new molecules. |
De novo design, scaffold hopping, library expansion. |
Enables exploration of novel chemical space. |
Synthesizability not always guaranteed; validation needed. |
|
Knowledge-Graph AI |
Networks linking biological/chemical entities. |
Target identification, drug repurposing. |
Integrates heterogeneous data sources. |
Strongly dependent on curated datasets. |
|
Natural Language Processing (NLP) |
Extraction of information from literature and patents. |
Target–disease association mining, hypothesis generation. |
Utilizes vast unstructured data. |
May propagate errors from weak text sources. |
|
Federated Learning |
ML training across distributed datasets without centralised data sharing. |
Collaborative pharma research, rare disease datasets. |
Protects confidentiality, improves data diversity. |
Technical complexity; regulatory considerations. |
3. APPLICATIONS OF AI ACROSS THE DRUG DISCOVERY PIPELINE
This section outlines the main stages of drug discovery and development and describes how AI is applied at each stage, supported by recent literature. The following pipeline breakdown is adopted.
3.1 Target Identification and Validation
Identifying a valid biological target (gene, protein, pathway) that is druggable and relevant to disease mechanism is a foundational step. Traditional methods involve experimental screens, literature mining, and expert hypothesis generation. AI introduces several enhancements:
3.2 Virtual Screening and Lead Discovery
Once a target is identified, the next step is to discover compounds (“hits”) that modulate the target. Virtual screening (VS) is the computational counterpart of high-throughput screening (HTS). AI enhances screening in multiple ways:
3.3 Lead Optimisation and De novo Design
Leads must be optimised for potency, selectivity, PK/PD (pharmacodynamics/ pharmacokinetics), safety, manufacturability and more. AI again plays multiple roles:
Despite progress, lead optimisation remains challenging: Chemical synthesizability, patentability, off?target effects, metabolism, regulatory concerns all complicate translation of AI-designed molecules. (1) emphasise that meaningful progress depends on integration of AI proposals with expert chemist input, experimental validation and feasibility filters.
3.4 Drug Repurposing
Drug repurposing (also called repositioning) refers to the identification of new therapeutic indications for existing drugs. The advantages: shorter development timelines, cheaper cost, known safety profiles. AI amplifies repurposing by:
Repurposing is a relatively low-risk entry point for AI in drug discovery because many compounds already exist; the main challenge becomes matching them to new disease contexts. AI helps to accelerate hypothesis generation and prioritisation, reducing the cost and time of screening.
3.5 ADME / Toxicity (Safety) Prediction
One of the major causes of failure in drug development is inadequate pharmacokinetics (absorption, distribution, metabolism, excretion; ADME) or unacceptable toxicity. AI contributes by:
Despite the promise, predictions remain probabilistic; real?world translation still demands thorough experimental and in-vivo validation. Model interpretability and the availability of robust training datasets remain key bottlenecks for safety prediction models (1).
3.6 Clinical Trial Design, Patient Stratification and Real-World Evidence
Beyond early discovery, AI is increasingly applied in the later phases of drug development: clinical trials, patient recruitment, biomarker discovery and real-world data (RWD) analysis. Key applications include:
Thus, AI helps bridge the gap between bench and bedside, improving the entire therapeutic development lifecycle. Table 2 summarizes the integration of AI-driven approaches across multiple stages of the drug discovery pipeline, including target identification, virtual screening, lead optimization, and clinical development. It illustrates how AI methodologies enhance predictive accuracy, streamline workflows, and reduce development timelines, thereby improving efficiency and decision-making in pharmaceutical research (1, 24)
Table 2. AI Applications across the drug discovery pipeline
|
Drug Discovery Stage |
AI Role |
Example Methods |
Expected Benefits |
|
Target Identification |
Identify disease-relevant genes/proteins using multi-omics integration. |
Knowledge graphs, ML clustering, NLP. |
Higher confidence in target selection. |
|
Virtual Screening |
Predict hit molecules and filter large chemical libraries. |
DL models, GNNs, ML-based scoring functions. |
Faster, cheaper, more accurate screening. |
|
Lead Optimisation |
Predict activity, ADME/Tox, design modifications. |
Multi-task DL, reinforcement learning, generative models. |
Reduced synthetic cycles, multi-parameter optimisation. |
|
De Novo Design |
Generate novel molecules with desired properties. |
VAE, GAN, diffusion models. |
Innovative scaffolds, IP advantages. |
|
Repurposing |
Identify new indications for existing drugs. |
DTI prediction models, knowledge graphs, network analysis. |
Lower development cost and time. |
|
ADME/Tox Prediction |
Predict safety, metabolism, clearance. |
DL toxicity models, ML ADMET predictors. |
Reduces late-stage failures. |
|
Clinical Trial AI |
Patient stratification, adaptive design. |
ML on EHR data, survival analysis models. |
Increased trial success, precision medicine. |
4. CHALLENGES, LIMITATIONS AND ENABLERS
While AI offers enormous promise in drug discovery, significant hurdles remain before it becomes a standard, reliable tool. In this section we examine key challenges and enabling factors.
4.1 Data Quality, Quantity and Curation
AI models are only as good as the data on which they are trained. Issues include:
Effective curation, standardisation, data sharing (while respecting IP/confidentiality) and generation of large, diverse training sets are essential enablers for AI in drug discovery.
4.2 Interpretability and Transparency
Deep learning models often behave as “black boxes”, which undermines trust in high-stakes decisions. In drug discovery, decisions such as “select this compound” or “advance this target” require scientific rationale. Key issues:
Thus, ensuring transparency and interpretability of AI models is critical for scientific adoption, regulatory acceptance and cross-discipline collaboration (chemists, biologists, AI scientists).
4.3 Integration with Experimental and Medicinal Chemistry Workflows
AI cannot replace experimental validation or expert human judgement. Key integration issues include:
Successful deployment of AI in drug discovery requires seamless collaboration among AI specialists, medicinal chemists, pharmacologists, and biologists (4).
4.4 Regulatory, Ethical and IP Considerations
Given the stakes in drug development (patient safety, high cost, regulatory scrutiny), AI introduces additional layers of complexity:
4.5 Evaluation Metrics and Benchmarking
Standardised evaluation of AI models in drug discovery remains a challenge. Some issues:
4.6 Organisational and Cultural Barriers
Adopting AI in pharmaceutical organisations brings its own challenges:
Nevertheless, many organisations now recognise that AI is essential for future competitiveness (28-29). These challenges highlight the need for hybrid approaches combining AI predictions with experimental validation to ensure reliable and translational outcomes in drug discovery.
5. FUTURE PERSPECTIVES AND EMERGING TRENDS
Looking forward, several emerging trends are likely to shape the future of AI in drug discovery:
5.1 Generative Chemistry and Automated Synthesis
Generative artificial intelligence is rapidly advancing, with methods such as diffusion models, transformer-based architectures, and reinforcement learning increasingly capable of proposing novel molecular structures under multiple constraints, including bioactivity, ADME properties, and synthetic feasibility (8). The integration of generative models with automated synthesis platforms, such as robotic chemistry systems, holds the potential to enable closed-loop design–synthesis–testing workflows. These developments highlight generative chemistry as a rapidly evolving field with significant promise for future drug discovery.
5.2 Multi-Modal and Multi-Scale Data Integration
Future workflows will increasingly integrate diverse data types: sequence, structure, omics, phenotypic imaging, EHR, literature. Multi-modal deep-learning models will enable richer representations and predictions. For example, integrating single-cell transcriptomics, proteomics and chemical structure to predict drug response in patient subgroups.
5.3 Federated Learning, Privacy-Preserving AI and Data Sharing
Because much pharmaceutical data is proprietary, federated learning and other privacy-preserving approaches will be central to collaborative AI development across institutions. This enables model training on distributed datasets without sharing raw data, enabling richer models while preserving confidentiality (30).
5.4 Explainable, Trustworthy and Responsible AI
As AI becomes more embedded in drug discovery, demands for interpretability, robustness, fairness and auditability will intensify. Model certification, uncertainty quantification, and clearly documented decision pathways will build trust across stakeholders (31). In parallel, regulatory frameworks may evolve to include AI-specific guidance in drug development.
5.5 AI-Enabled Clinical Trials and Real-World Evidence (RWE)
Beyond drug discovery, artificial intelligence is increasingly shaping clinical development and post-marketing surveillance through adaptive clinical trial designs, patient stratification and enrichment strategies, digital biomarker discovery, real-world evidence (RWE) analytics, and predictive monitoring of drug safety and efficacy, thereby accelerating translational pipelines and improving clinical outcomes (24, 32).
5.6 Small Molecule, Biologics, Cell & Gene Therapies
While much early AI work focused on small-molecule drug discovery, future applications will extend to biologics (antibodies, peptides), cell & gene therapies, and RNA-based modalities. These modalities present additional complexities (structure, delivery, immunogenicity) where AI can arguably add value.
5.7 Digital Twins and In Silico Clinical Trials
An ambitious horizon involves digital-twin models of human physiology and virtual clinical populations, enabling in silico trials guided by AI predictions. While still nascent, such frameworks could drastically reduce cost and time of development. The convergence of artificial intelligence, automation, and systems biology is expected to redefine the paradigm of drug discovery in the coming decade.
CONCLUSION
The application of artificial intelligence to drug discovery is no longer speculative—it is already reshaping how the pharmaceutical industry identifies targets, screens and designs compounds, predicts safety and efficacy, and designs clinical trials. From target identification leveraging knowledge-graphs and omics data to de novo generative chemistry, AI brings enhanced speed, improved prediction accuracy, and cost-efficiencies. Nevertheless, AI is not a magic bullet. Significant challenges remain: data quality and curation, model interpretability, integration with experimental workflows, regulatory and ethical considerations, and organizational adoption.We are moving toward a frontier where AI and robotics synergize with shared data and human experience to drive the next wave of innovation. Integrative frameworks that link generative design, automated synthesis, multi?modal data and iterative learning will pave the way for next-generation therapeutics. For academic researchers and industry alike, the imperative is clear: invest in data infrastructure, cultivate cross-disciplinary expertise, adopt transparent AI workflows, and rigorously validate models prospectively. If these prerequisites are met, AI holds the promise to deliver safer, more effective, and more affordable medicines to patients in less time. AI-driven drug discovery is poised to transition from a supportive tool to a central pillar of pharmaceutical innovation.
REFERENCES
Dipak Patil, Applications of Artificial Intelligence in Drug Discovery: Current Advances, Challenges, and Future Perspectives, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 4, 2711-2722, https://doi.org/10.5281/zenodo.19627749
10.5281/zenodo.19627749
